Royalty Pharma
RPRX
236 hedge funds and large institutions have $10.3B invested in Royalty Pharma in 2021 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 91 increasing their positions, 57 reducing their positions, and 33 closing their positions.
70% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 33
60% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 57
10% more funds holding
Funds holding: 214 → 236 (+22)
0.01% more ownership
Funds ownership: 63.73% → 63.75% (+0.01%)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
28% less call options, than puts
Call options by funds: $34.6M | Put options by funds: $48M
31% less capital invested
Capital invested by funds: $15B → $10.3B (-$4.72B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$114M |
| 2 |
Janus Henderson Group
London,
|
+$107M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$78.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77.8M |
| 5 |
JP Morgan Chase
New York
|
+$64.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$164M |
| 2 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$152M |
| 3 |
BlackRock
New York
|
-$144M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$83.6M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$82.3M |
RPRX Hedge Fund Activity: Q2 2021 in Review
236 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2021, worth a combined $10.3B — down 31% from $15B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new RPRX positions and 33 closed out — a net gain of 23 holders — while 91 added to existing stakes and 57 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $114M. The largest seller was Fidelity Investments, cutting an estimated $164M.
- 236 institutional investors held Royalty Pharma (RPRX) as of Q2 2021, up from 214 in Q1 2021.
- Funds reported $10.3B of Royalty Pharma stock for Q2 2021, down 31% quarter-over-quarter.
- 56 funds opened new Royalty Pharma positions in Q2 2021 and 33 closed out, a net change of +23 holders.
- The largest Royalty Pharma buyer in Q2 2021 was Morgan Stanley, an estimated $114M added.
- The largest Royalty Pharma seller in Q2 2021 was Fidelity Investments, an estimated $164M sold.
Based on aggregated 13F filings for Q2 2021.